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Overexpression of connective tissue growth factor in
podocytes worsens diabetic nephropathy in mice
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Connective tissue growth factor (CTGF) is a potent inducer of
extracellular matrix accumulation. In diabetic nephropathy,
CTGF expression is markedly upregulated both in podocytes
and mesangial cells, and this may play an important role
in its pathogenesis. We established podocyte-specific
CTGF-transgenic mice, which were indistinguishable at
baseline from their wild-type littermates. Twelve weeks
after streptozotocin-induced diabetes, these transgenic mice
showed a more severe proteinuria, mesangial expansion,
and a decrease in matrix metalloproteinase-2 activity
compared to diabetic wild-type mice. Furthermore, diabetic
transgenic mice exhibited less podocin expression and
a decreased number of diffusely vacuolated podocytes
compared to diabetic wild-type mice. Importantly, induction
of diabetes in CTGF-transgenic mice resulted in a further
elevation of endogenous CTGF mRNA expression and
protein in the glomerular mesangium. Our findings
suggest that overexpression of CTGF in podocytes is
sufficient to exacerbate proteinuria and mesangial expansion
through a functional impairment and loss of podocytes.
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Diabetic nephropathy is a major complication in diabetes
and the leading cause of end-stage renal disease worldwide.1
Diabetic nephropathy is characterized by microalbuminuria,
renal and glomerular hypertrophy, mesangial expansion with
increased thickness of the glomerular basement membrane
(GBM), arteriolar hyalinosis, and global glomerular sclerosis,
which ultimately cause the progression of proteinuria and
renal failure.2 Accumulation of the extracellular matrix
(ECM) components in the mesangium, GBM, and tubu-
lointerstitium plays an important role in its pathology.3,4
Evidence has shown that such renal lesions are driven, in
part, by transforming growth factor-b (TGF-b) in humans
and experimental models.4–6 Recently, functional and struc-
tural abnormalities in glomerular podocytes have become
highlighted as one of the earliest events in the development of
diabetic glomerular injury.7 Podocyte loss and injury are
found at very early stages in patients with diabetic
nephropathy, being associated with the acceleration of
glomerular structural abnormalities.8 Causes and consequences
of podocyte injury during early diabetic nephropathy, however,
remain poorly understood.
Connective tissue growth factor (CTGF, also known
as CCN2) belongs to a family of cysteine-rich growth
factors, the CCN family, that consists of cysteine-rich
protein 61 (Cyr61/CCN1), CTGF/CCN2, nephroblastoma
overexpressed (Nov/CCN3), and Wnt-induced secreted
proteins (WISP)-1, 2, and 3 (CCN4, 5, and 6, respec-
tively).9–11 Accumulating evidence has demonstrated that
CTGF is crucially involved in the fibrogenic properties
of TGF-b.12–14 CTGF gene expression is strongly induced by
TGF-b, and recombinant CTGF potently stimulates fibroblast
proliferation and ECM protein synthesis.12–16 TGF-b-induced
collagen synthesis in vitro is shown to be CTGF dependent,
which is shown by a neutralizing antibody or the antisense
gene targeting CTGF.17 Furthermore, we have demonstrated
in vivo that knockdown of CTGF gene expression with
antisense gene transfer into rat kidney ameliorates tubuloin-
terstitial fibrosis in obstructive nephropathy.18 CTGF has
been proposed to be a crucial mediator for the development
of diabetic glomerulosclerosis.19–24 CTGF mRNA is mainly
expressed at podocytes and detected in some parietal
epithelial cells of glomeruli under normal conditions in
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humans24 and rats.13 Under the diabetic milieu, CTGF
expression is markedly upregulated in podocytes, mesangial
cells, and tubulointerstitial cells, being associated with
fibrotic lesions and epithelial-to-mesenchymal transforma-
tion.19–24 CTGF may also enhance ECM accumulation
through inhibition of matrix degradation.25 Although these
observations are consistent with CTGF as a key mediator of
the progression of diabetic nephropathy, the precise role of
CTGF in diabetic glomeruli, especially in podocytes, still
remains elusive.
To explore the roles of CTGF in podocytes and in diabetic
nephropathy, we generated a transgenic mouse model
harboring the podocyte-specific expression of the CTGF
gene under the control of the nephrin promoter. We
demonstrated acceleration of diabetic nephropathy in
CTGF-overexpressing mice, indicating that dysregulated
expression of CTGF in podocytes may play a role in
mesangial expansion and podocyte loss in diabetic nephro-
pathy.
RESULTS
Generation of podocyte-specific CTGF-transgenic mice
We constructed a transgene using a fragment of the human
nephrin gene (Nphs1),26 rabbit b-globin intron, mouse CTGF
cDNA, and polyA signal (Figure 1a). Transgenic founder lines
carrying the human Nphs1 promoter-mouse CTGF transgene
were identified by Southern blot analysis. We obtained five
founder CTGF-transgenic (CTGF-Tg) mice, and semiquanti-
tative analysis showed 10 (line 30), 10 (line 68), 15 (line 56),
20 (line 52), and 5 (line 12) transgene copies in these mice
(Figure 1b). Northern blot analyses for CTGF revealed that
the transgene was expressed abundantly in the isolated
glomeruli of CTGF-Tg mice, but not in other tissues,
including aorta, brain, heart, lung, liver, spleen, stomach,
and pancreas (Figure 1c). The size of transgene-derived
CTGF mRNA (1.7 kb) was smaller than the endogenous one,
because we used only CTGF coding region (Figure 1c). The
glomerular CTGF protein level in CTGF-Tg mice (line 12)
was five times higher than that in wild-type mice (Figure 1d).
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Figure 1 | Construction of podocyte-specific CTGF transgenic mice. (a) Schematic structure of the transgene. The transgene construct
carried a 1.2-kb fragment of Nphs1 promoter, b-globin intron, 1.1-kb mouse CTGF cDNA, and b-globin polyA. (b) Southern blot analysis of
genomic DNA extracted from the mouse tail and digested with NotI. Five founder mouse lines were identified, and the 1.2-kb transgene
(arrowhead) was present in lines 30, 68, 56, 52, and 12. An arrow indicates the genomic CTGF gene. WT, wild-type mice. (c) Northern blot
analysis of CTGF mRNA in the glomeruli of wild-type and CTGF-transgenic mice (CTGF-Tg mice) lines 30, 68, 56, 52, and 12 (upper panel), and in
the aorta, brain, heart, lung, liver, spleen, stomach, whole kidney, glomeruli, and pancreas of CTGF-Tg mice line 12 (lower panel). The size of
CTGF mRNA expression from the transgene is 1.7 kb (arrowhead), which is smaller than the endogenous one (2.3 kb, arrow). (d) Western blot
analysis of CTGF protein in the glomeruli of wild-type and CTGF-Tg mice line 12. TG, CTGF-Tg mice. (e–h) Histological examination and
immunohistochemical study for CTGF in the kidney of non-Tg mice and CTGF-Tg mice line 12. Light microscopy of the kidney from
non-Tg mice (e) and CTGF-Tg mice (f) with periodic acid–Schiff staining. Immunofluorescent examination of CTGF showed CTGF
upregulation at podocytes in CTGF-Tg mice (h) compared with non-Tg mice (g).
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All CTGF-Tg mice were fertile, grew normally, and
showed normal gross appearance including kidney size and
renal histology, as represented in line 12 (Figure 1f).
Immunofluorescent analysis revealed that CTGF expression
in podocytes was upregulated compared with their non-
transgenic (non-Tg) littermates (Figure 1g and h). Blood
pressure, blood glucose, serum creatinine, urea nitrogen, and
urinary albumin excretion in CTGF-Tg mice line 12 were not
different from those in control non-Tg littermates (Table 1).
Another CTGF-Tg line (line 52) showed essentially similar
results (data not shown).
Characteristics of diabetic CTGF-transgenic mice
Next, to examine the role of CTGF expressed at podocytes in
diabetic nephropathy, we induced diabetes in these mice by
intraperitoneal injection of streptozotocin. We used CTGF-
Tg mice line 12 and line 52, both with high transgene
expression, in this experiment. Blood glucose, HbA1c, and
serum creatinine levels as well as body weights in diabetic
CTGF-Tg mice were not different from those in diabetic non-
Tg mice at 12 weeks after disease induction (Table 2).
Diabetic CTGF-Tg mice exhibited a tendency of renal
hypertrophy compared with diabetic non-Tg mice, as shown
by the increased kidney weight to body weight ratio. Systolic
blood pressure and urine volume were not significantly
different among diabetic groups. All diabetic groups showed
increased albuminuria by 4 weeks after induction. Interest-
ingly, diabetic CTGF-Tg mice revealed more pronounced
elevation of urinary albumin excretion than diabetic non-Tg
mice at 4 weeks, and became more aggravated during the
experimental period (Figure 2). At 12 weeks, diabetic non-Tg
mice exhibited 3.6-fold higher albumin excretion than non-
diabetic control, and both lines of diabetic CTGF-Tg mice
revealed significantly enhanced albuminuria by 2.8-fold
compared with diabetic non-Tg mice (Figure 2). These
results indicate that overexpression of CTGF in podocytes
enhances proteinuria in diabetic nephropathy.
Glomerular extracellular matrix accumulation and podocyte
injury in diabetic CTGF-Tg mice
Microscopic examination showed that diabetic mice at 12
weeks after induction of diabetes exhibited marked mesangial
expansion with glomerular hypertrophy (Figure 3c and d).
Morphometric analysis revealed a significant increase in the
mesangial area of diabetic CTGF-Tg mice line 12 compared
with diabetic non-Tg mice (Figure 3f).
In electron microscopic analysis, podocytes of both lines
of diabetic CTGF-Tg mice revealed diffuse vacuolation
(Figure 4b and c), which was rarely observed in diabetic
non-Tg mice (Figure 4a) or non-diabetic CTGF-Tg mice. The
thickness of the GBM was similar among diabetic groups
(Figure 4d–f). Thus, CTGF overexpressed at podocytes causes
enhanced mesangial matrix expansion and podocyte struc-
tural changes under diabetic conditions.
Effect of CTGF overexpression on gene and protein
expression in glomeruli
Since we found enhanced ECM accumulation in diabetic
CTGF-Tg mice compared with diabetic non-Tg mice, we
investigated glomerular expression of total CTGF, endogen-
ous CTGF, and TGF-b1, which are key inducers of ECM, as
well as fibronectin, a1(IV) collagen (COL4A1), and a3(IV)
collagen (COL4A3), which are representative ECM compo-
nents. Total CTGF indicates the sum of transgene-derived
Table 1 | Baseline characteristics of non-Tg and CTGF-Tg mice
Non-Tg
mice
CTGF-Tg mice
line 12
Body weight (g) 20.8±1.6 20.0±0.4
Systolic blood pressure (mm Hg) 108.5±3.4 108.0±2.5
Blood glucose (mg per 100 ml) 162±11 151±11
Serum creatinine (mg per 100 ml) 0.12±0.01 0.13±0.01
Serum urea nitrogen (mg per 100 ml) 30.7±2.6 30.7±3.5
Urine volume (ml per day) 1.0±0.2 1.3±0.2
Urinary albumin excretion
(mg per mg Cr)
41.3±4.2 42.8±5.4
CTGF, connective tissue growth factor; Tg, transgenic.
Values are expressed as the mean±s.e. for non-Tg mice (n=13) and CTGF-Tg mice
line 12 (n=9).
Table 2 | Characteristics of diabetic mice at 12 weeks after induction of diabetes
Control Diabetes
Non-Tg Tg line 12 Tg line 52 Non-Tg Tg line 12 Tg line 52
Blood glucose (mg per 100 ml) 144±14 123±20 106±16 732±134* 718±48* 804±156*
HbA1c (%) 3.3±0.2 3.1±0.2 2.9±0.2 11.4±0.7* 10.0±0.5* 9.3±1.8*
Serum creatinine (mg per 100 ml) 0.16±0.02 0.14±0.01 0.17±0.02 0.21±0.03# 0.25±0.03# 0.24±0.06#
Serum urea nitrogen (mg per 100 ml) 25.7±1.8 24.3±2.3 29.6±3.0 49.7±2.5* 44.0±3.6* 50.6±±10.4*
Body weight (g) 24.6±1.8 25.7±0.6 23.1±1.0 23.1±0.5 22.1±2.2 22.2±0.4
Kidney weight (g) 0.14±0.02 0.13±0.01 0.12±0.02 0.22±0.02* 0.22±0.01* 0.24±0.05*
Kidney weight/body weight ratio
(g per 100 g BW)
0.56±0.02 0.52±0.02 0.47±0.02 0.96±0.04* 0.99±0.09* 1.04±0.04*
Systolic blood pressure (mm Hg) 105.4±1.1 107.2±0.3 110.3±0.3 108.2±0.3 108.6±1.0 110.8±1.6
Urine volume (ml per day) 1.1±0.3 1.2±0.4 0.5±0.5 32.1±0.9* 26.6±7.4* 25.8±5.3*
BW, body weight; Hb, hemoglobin; Tg, transgenic.
Values are expressed as the mean±s.e. for control non-Tg mice (n=4), control CTGF-Tg mice line 12 (n=5), control CTGF-Tg mice line 52 (n=5), diabetic non-Tg mice (n=10),
diabetic CTGF-Tg mice line 12 (n=8), and diabetic CTGF-Tg mice line 52 (n=7).
*Po0.01 vs control non-Tg mice.
#Po0.05 vs control non-Tg mice.
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and endogenous CTGF. Total CTGF expression in glomeruli
from non-diabetic CTGF-Tg mice was upregulated by 2.5-
fold compared with control non-Tg mice (Figure 5a). In
diabetic CTGF-Tg mice, total CTGF mRNA expression was
significantly upregulated by 4.0-fold compared with diabetic
non-Tg mice (Figure 5a). Endogenous CTGF expression in
diabetic CTGF-Tg mice was 3.0 times higher than that
in diabetic non-Tg mice, indicating that CTGF upregulation
in diabetic CTGF-Tg mice was due to the increase of
endogenous CTGF. Fibronectin mRNA expression in glome-
ruli was increased in diabetic mice, but the levels were not
significantly different between diabetic CTGF-Tg and diabetic
non-Tg mice (Figure 5a). TGF-b1 and COL4A1 mRNA
expressions in glomeruli also increased or tended to increase
in diabetic conditions, but there was no significant difference
among diabetic groups. There was no significant alteration in
COL4A3 mRNA expression between CTGF-Tg and non-Tg
mice in diabetic or non-diabetic conditions (Figure 5a). Next,
we investigated glomerular expression of ECM degradation
enzymes. Matrix metalloproteinase (MMP)-2 mRNA expres-
sion in glomeruli was significantly increased in diabetic
condition (Figure 5a). In diabetic CTGF-Tg mice, MMP-2
mRNA expression was reduced compared with diabetic non-
Tg mice. Expressions of tissue inhibitor of metalloproteinase
(TIMP)-1 and -2, inhibitors of MMPs, were also upregulated
in diabetic conditions, but there was no significant difference
among diabetic groups. We next examined glomerular MMP-
2 activity in diabetic CTGF-Tg mice, using gelatin zymo-
graphy. The gelatinase activity of pro- and active- MMP-2
was significantly elevated in diabetic non-Tg mice (Figure
5b). In diabetic CTGF-Tg mice, the gelatinase activity was
significantly decreased compared with diabetic non-Tg mice
(Figure 5b). These findings suggest that CTGF causes ECM
accumulation in mesangium by suppression of degradation
rather than by enhancement of ECM expression itself.
The number of podocytes was evaluated by immuno-
histochemical study for the Wilms’ tumor gene (WT1). The
number of WT1-positive cells was significantly (by 29%) low
in a glomerular cross-section of diabetic CTGF-Tg mice line 12
(Figure 6d) than in diabetic non-Tg mice (Figure 6c). CTGF-Tg
line 52 showed virtually similar results (not shown).
Immunofluorescent study revealed that in diabetic non-Tg
mice CTGF expression was upregulated in podocytes and
mesangial cells (Figure 7c). Diabetic CTGF-Tg mice showed
further increased CTGF protein expression in podocytes
and mesangial cells compared with diabetic non-Tg mice
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Figure 2 | Urinary albumin excretion after induction of diabetes
in CTGF-Tg mice and non-Tg mice. The open circles, squares, and
triangles represent vehicle-treated non-Tg mice, CTGF-Tg mice line
12, and CTGF-Tg line 52, respectively. The closed circles, squares,
and triangles represent diabetic non-Tg mice, CTGF-Tg mice
line 12, and CTGF-Tg line 52, respectively. Urinary albumin excretion
showed a marked increase in diabetic CTGF-Tg mice throughout
the course. Mean±s.e. for control non-Tg mice (n¼ 4), control
CTGF-Tg mice line 12 (n¼ 5), control CTGF-Tg mice line 52 (n¼ 5),
diabetic non-Tg mice (n¼ 10), diabetic CTGF-Tg mice line 12 (n¼ 8),
and diabetic CTGF-Tg mice line 52 (n¼ 7). *Po0.01, versus
non-diabetic CTGF-Tg mice in the same genotype at each time
point; **Po0.01, versus non-diabetic non-Tg mice at each time
point; and #Po0.05, ##Po0.01, versus diabetic non-Tg mice at each
time point.
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Figure 3 | Histological examination of streptozotocin-induced
diabetic nephropathy in CTGF-Tg mice. Representative views on
light microscopy at 12 weeks after induction of diabetes of
the kidneys from (a) non-diabetic non-Tg mice, (b) non-diabetic
CTGF-Tg mice line 12, (c) diabetic non-Tg mice, (d) and diabetic
CTGF-Tg mice line 12 are shown. The kidney sections were stained
with periodic acid–Schiff. (e) Glomerular cross-sectional area (f) and
mesangial area at 12 weeks after induction of diabetes. Values
were expressed as the mean±s.e. for control non-Tg mice (n¼ 4),
control CTGF-Tg mice line 12 (n¼ 5), diabetic non-Tg mice (n¼ 10),
and diabetic CTGF-Tg mice line 12 (n¼ 8). *Po0.05, **Po0.01,
and #Po0.05.
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(Figure 7c and d). Immunostaining of podocin became
downregulated in diabetic CTGF-Tg mice as compared with
diabetic non-Tg mice (Figure 7g and h). Double immunos-
taining for CTGF and podocin showed that CTGF protein in
non-diabetic CTGF-Tg mice was located mainly in podocytes
(yellow) (Figure 7j) and that CTGF was increased in the
mesangial area in diabetic CTGF-Tg mice (green) (Figure 7l).
These findings suggest that CTGF overexpression at podo-
cytes resulted in loss of and functional impairment of
podocytes and augmented induction of CTGF mainly at
the mesangial area in streptozotocin-induced diabetic
nephropathy.
DISCUSSION
In this study, to clarify the role of CTGF in diabetic
nephropathy, we have generated podocyte-specific CTGF-Tg
mice under the control of the human nephrin promoter.26
Glomerular expressions of CTGF mRNA and protein of
CTGF-Tg mice were increased 2.5 and 5 times, respectively,
compared with non-Tg mice. Immunofluorescent analysis
revealed that CTGF expression was upregulated at podocytes
in CTGF-Tg mice. Both lines of CTGF-Tg mice exhibited
normal blood pressure, serum urea nitrogen, and urinary
albumin excretion levels as well as normal renal histology,
suggesting that increased CTGF expression at podocytes
alone is not sufficient to evoke renal abnormality.
After induction of diabetes, CTGF-Tg mice exhibited
enhanced CTGF mRNA expression by 4.0-fold as compared
with diabetic non-Tg mice. In contrast, non-diabetic CTGF-
Tg mice showed only 2.5-fold elevated CTGF mRNA
compared with control, non-Tg mice. The origin of CTGF
upregulation in diabetic CTGF-Tg mice was mainly endo-
genous CTGF in glomeruli determined by real-time reverse
transcription-PCR (RT-PCR). Immunofluorescent staining
for CTGF also revealed that diabetic CTGF-Tg mice exhibited
enhanced CTGF expression mainly in the mesangial area.
Such upregulation of CTGF expression associated with
diabetes suggests a ‘vicious cycle’ whereby transgene-derived
CTGF induces endogenous CTGF gene expression. It has
already been shown that CTGF administration stimulates
CTGF expression in cultured mesangial cells,19 supporting
this hypothesis.
Diabetic CTGF-Tg mice showed significantly increased
mesangial expansion. Several lines of evidence indicate that
humoral factors produced by podocytes have effects on
mesangial and endothelial cells. Quaggin et al.27 have
reported that heterozygous disruption of vascular endothelial
growth factor allele in podocytes results in endothelial cell
damages and mesangial expansion. Another report showed
that podocyte-specific injury in adult mice leads to mesangial
expansion and glomerulosclerosis.28 Taken together, it is well
conceivable that CTGF produced by podocytes should exert
an effect on mesangial cells to stimulate CTGF expression and
ECM accumulation in diabetic conditions. CTGF has been
shown to inhibit ECM degradation in mesangial cells
and fibroblasts.12,19,25 This study showed that glomerular
COL4A3 or fibronectin mRNA expression was not changed
among diabetic groups. Of note, glomerular MMP-2 mRNA
expression in diabetic CTGF-Tg mice was significantly
decreased compared with diabetic non-Tg mice. Glomerular
MMP-2 activity in diabetic CTGF-Tg mice was also reduced
compared with diabetic non-Tg mice. MMP-2 mRNA
expression has been shown to be located in mesangial cells,
as well as in visceral epithelial, glomerular epithelial, and
endothelial cells in the kidney from patients of type I diabetes
with diabetic nephropathy.29 Our results, that the reduced
activity of MMP-2 in glomeruli is associated with mesangial
expansion in diabetic CTGF-Tg mice, may be consistent with
this finding. Although the mechanism for the enhanced
mesangial expansion in CTGF-Tg mice should await further
clarification, our study suggests that the enhanced mesangial
expansion in diabetic CTGF-Tg mice may be due to
inhibition of ECM degradation through decreased expression
and activity of MMP-2.
Increased CTGF expression has already been demon-
strated in various cell types of human and rodent diabetic
kidneys,19–24,30,31 providing one of potential mechanisms for
development and progression of diabetic nephropathy. High
333 nm 333 nm 333 nm
Figure 4 | Electron microscopic analysis of a glomerulus in diabetic nephropathy in CTGF-Tg mice. Diabetic non-Tg mice showed
intact podocytes (a), no vacuolar formation, and almost normal foot process structure with mild thickening of the GBM (d). Diabetic CTGF-Tg
(b, line 12; c, line 52) contained several vacuoles in podocytes (arrows; b and c). However, foot process structure was well maintained
with mild GBM thickening (e, line 12; f, line 52).
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glucose stimulation induces CTGF mRNA in human and
rat mesangial cells.19,21,30 Advanced glycation end products
also induce CTGF mRNA and protein in mesangial cells,
through a TGF-b-independent pathway.31,32 Furthermore,
plasma and urinary CTGF levels are significantly increased
in type I diabetic patients with nephropathy.33 Very recently,
Guha et al.34 have reported that downregulation of
CTGF using antisense oligonucleotide attenuates urinary
albuminuria and ECM accumulation in diabetic mice. The
present study reveals that overexpression of CTGF in
podocytes enhances urinary albumin excretion in the diabetic
milieu, indicating that augmented podocyte expression of
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Figure 5 | Glomerular mRNA expressions and MMP-2 zymographic activity. (a) Real-time RT-PCR analyses of CTGF (total), CTGF
(endogenous), TGF-b1, fibronectin (FN), a1(IV) collagen (COL4A1), a3(IV) collagen (COL4A3), matrix metalloproteinase 2 (MMP-2), tissue
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control non-Tg mice (n¼ 4), control CTGF-Tg mice line 12 (n¼ 5), diabetic non-Tg mice (n¼ 10), and diabetic CTGF-Tg mice line 12
(n¼ 8). *Po0.05, **Po0.01, #Po0.05, and ##Po0.01. (b) Representative gelatin zymography performed 12 weeks after induction of diabetes.
A mixture of human MMP-2 and MMP-9 served as a standard (std). Densitometric analysis of pro- and active forms of MMP-2 (72 and
62 kDa) activity (n¼ 4). *Po0.05, **Po0.01.
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CTGF accelerates advancement of diabetic nephropathy
(Figure 8).
Diabetic CTGF-Tg mice showed podocyte loss as com-
pared with diabetic non-Tg mice by the immunohistochem-
ical study of WT1. Kidney biopsies from type II diabetic
patients have shown that the number of podocytes is reduced
at the microalbuminuria stage and is gradually decreased
with the progression of diabetic nephropathy,8 through, at
least in part, the detachment from the GBM.7 Overexpression
of CTGF at podocytes in the current study may have
facilitated the podocyte detachment under the diabetic
milieu. Our study has also demonstrated that, by electron
microscopy, both lines of diabetic CTGF-Tg mice reveal
diffuse vacuolar formation in podocytes, which was rarely
observed in diabetic non-Tg mice. Vacuolar degeneration of
podocytes has already been shown in diabetic ZDF-fa/fa
rats.35 In addition, renal biopsy specimens from patients with
focal segmental glomerulosclerosis (FSGS) or membranous
nephropathy show the vacuolar degeneration in podo-
cytes,36,37 and FSGS patients with podocyte vacuolation tend
to develop chronic renal failure.36 Taken together, diabetic
CTGF-Tg mice showed accelerated podocyte injury with the
overexpression of CTGF under diabetic condition.
Podocin, coded by the Nphs2 gene, is identified as a
causative gene responsible for a familial form of early-onset,
steroid-resistant nephrotic syndrome.38 Podocin-deficient
mice show proteinuria, mesangial sclerosis, and podocyte
foot process fusion,39 indicating that podocin is essential for
maintaining normal glomerular structure and function. In
this study, podocin protein expression was reduced
in diabetic CTGF-Tg mice, which may reflect podocyte loss.
In summary, this study reveals that overexpression of
CTGF at podocytes in mice causes enhanced albumin
excretion and mesangial expansion, podocyte loss and
vacuolar degeneration, and downregulation of podocin
protein under the diabetic milieu. These findings are
consistent with an important role for CTGF in the
development of diabetic nephropathy in vivo and suggest
that CTGF can be a promising therapeutic target against
diabetic nephropathy.
MATERIALS AND METHODS
Generation of podocyte-specific CTGF-Tg mice
The 1.2-kb promoter of the human nephrin gene (Nphs1) capable of
podocyte-specific expression26 was PCR amplified from the human
genome using the following primers: 50-ctgaggcagatggatcacctgagg-30
and 50-tcacaggtccccctactgtgaccc-30. The product was subcloned
into pSTBlue-1 AccepTor vector (Merck Biosciences, Darmstadt,
Germany) and the nucleotide sequence was confirmed. A 1.2-kb
HindIII/BamHI fragment of the pSTBlue-1-human nephrin pro-
moter was inserted into the transgene vector that contained a rabbit
b-globin intron and the polyadenylation site.40 HindIII and EcoRI
restriction sites of the vector were replaced with XhoI and NotI sites,
respectively. Full-length mouse CTGF cDNA was PCR amplified
from C57BL/6J mouse kidney cDNA using the following primers:
50-tcctaccgcgtcccgatcat-30 and 50-gctttacgccatgtctccgt-30. The 1.1-kb
PCR product was excised, subcloned into pGEM-T-Easy vector
(Promega, Madison, MI, USA), and ligated into the NotI site of the
transgene vector. The XhoI fragment of the fusion gene was
microinjected into the pronucleus of C57BL/6J mouse eggs.41
To identify founder mouse lines that carried the nephrin
promoter-CTGF transgene, Southern blot analysis was performed
using tail tissue DNA.41 CTGF mRNA expression was evaluated by
northern blot analysis.13,18 Briefly, total RNA was extracted using
Trizol reagent (Invitrogen, Carlsbad, CA, USA) from glomeruli that
were isolated by the graded sieving method.42,43 Hybridization
was performed with 32P-labeled probes for mouse CTGF cDNA
(nucleotides 119–1187).
Phenotypic analysis
All animal experiments were approved by the Animal Experimentation
Committee of Kyoto University Graduate School of Medicine.
CTGF-Tg mice (lines 12 and 52) and their non-Tg littermates were
followed up to 12 weeks of age and the samples were collected.
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Figure 6 | Immunohistochemical study of WT1 and number
of podocytes. (a) Non-diabetic non-Tg mice, (b) non-diabetic
CTGF-Tg mice line 12, (c) diabetic non-Tg mice, (d) and diabetic
CTGF-Tg mice line 12 at 12 weeks after induction of diabetes.
(e) Number of WT1-positive cells per glomerular cross-section was
counted. Diabetic CTGF-Tg mice had significantly fewer WT1-positive
cells per glomerular cross-section as compared with diabetic
non-Tg mice. Values were expressed as the mean±s.e. for control
non-Tg mice (n¼ 4), control CTGF-Tg mice line 12 (n¼ 5), diabetic
non-Tg mice (n¼ 10), and diabetic CTGF-Tg mice line 12 (n¼ 8).
*Po0.01, #Po0.01.
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Blood glucose and HbA1c values were determined from whole
venous blood taken from mouse tails in ad libitum-fed conditions
using an automatic glucometer (Glutest Ace, Sanwa Kagaku,
Nagoya, Japan)42 and DCA2000 analyzer (Bayer Medical, Tokyo,
Japan), respectively. For urine measurements, each animal was
housed separately in a metabolic cage (Shinano Manufacturing,
Tokyo, Japan). Urinary and serum creatinine levels were measured
by the enzymatic method (SRL, Tokyo, Japan).42 Urinary albumin
excretion was assayed with a murine albumin ELISA kit (Exocell,
Philadelphia, PA, USA).43
Induction of diabetes and experimental protocols
Twelve-week-old CTGF-Tg mice line 12 (non-diabetic, n¼ 5; diabetic,
n¼ 8), CTGF-Tg mice line 52 (non-diabetic, n¼ 5; diabetic, n¼ 7),
and their non-Tg littermates (non-diabetic, n¼ 4; diabetic, n¼ 10)
were fed on standard chow and given water ad libitum. Diabetes was
induced by three consecutive intraperitoneal injections of strepto-
zotocin (Sigma-Aldrich, Saint Louis, MO, USA; 100 mg per kg body
weight in citrate buffer, pH 4.0);21,42 control mice received citrate
buffer only. Mice with blood glucose levels higher than 300 mg per
100 ml were used as diabetic. Blood glucose levels and body weights
were measured every 4 weeks over a 12-week period. Mice were
killed at 24 weeks of age under ether anesthesia and samples were
collected for histological and biochemical analyses.
Renal histology and electron microscopy
Kidney sections were fixed with 4% buffered paraformaldehyde and
embedded in paraffin. One-mm-thick sections were stained with
periodic acid–Schiff and examined by light microscopy.43 The cross-
sectional area and the mesangial area of 20 glomeruli from the
outer cortex were measured quantitatively using a computer-aided
manipulator (KS400, Carl Zeiss Vision, Munich, Germany).43 The
procedure was performed by two investigators blind to the origin of
the slides, and the mean values were calculated. For electron
microscopy, small blocks of kidneys were fixed in 2.5% buffered
glutaraldehyde, post-fixed in 2% osmium tetroxide, dehydrated in
graded ethanol, and embedded in epoxy resin.44 Ultrathin sections
(0.1-mm thick) were stained with uranyl acetate/lead citrate and
examined in an electron microscope (H-7100, Hitachi, Tokyo,
Japan).
Immunohistochemistry
For double immunofluorescence analyses of CTGF and podocin,
4-mm cryostat sections fixed in cold acetone were treated with 0.1%
Triton X (Nacalai Tesque, Kyoto, Japan) for 10 min, followed by
incubation with human anti-CTGF antibody (a kind gift from Dr
N Oliver, FibroGen Inc., South San Francisco, CA, USA)20 and anti-
podocin antibody (Sigma-Aldrich) for 1 h. After incubation with
FITC-labeled donkey anti-human IgG (Jackson ImmunoResearch,
West Grove, PA, USA) and Texas Red-labeled anti-rabbit IgG
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Figure 7 | Double immunofluorescent staining for CTGF (green) and podocin (red). (a–d) CTGF, (e–h) podocin, and (i–l) merged images
in the kidney from (a, e, and i) non-diabetic non-Tg mice, (b, f, and j) non-diabetic CTGF-Tg mice line 12, (c, g, and k) diabetic non-Tg
mice, and (d, h, and l) diabetic CTGF-Tg mice line 12 at 12 weeks after induction of diabetes. CTGF protein expression was increased in
the mesangial area and podocytes of diabetic CTGF-Tg mice (d and l) as compared with diabetic non-Tg mice (c and k). Podocin staining
was well maintained in diabetic non-Tg mice (g). In contrast, podocin expression was partially reduced in diabetic CTGF-Tg mice line 12 (h).
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Figure 8 | Proposed mechanism of diabetic nephropathy.
Overexpression of CTGF at podocytes accelerates podocyte injury
in diabetic nephropathy and induces CTGF at mesangial cells, which
inhibits ECM degradation and leads to mesangial expansion.
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(Jackson ImmunoResearch), the slides were developed by a
fluorescence microscope (IX-81; Olympus, Tokyo, Japan). WT1
immunostaining was performed as described.45 More than 20
consecutive glomerular sections in each mouse were examined, and
the mean number of WT1-positive cells per glomerular cross-section
was calculated.
Glomerular RNA extraction and real-time RT-PCR analysis
Quantitative real-time RT-PCR was performed using one-step RT-
PCR master mix reagents on an ABI Prism 7700 Sequence Detector
(Applied Biosystems, Tokyo, Japan).46 Primers were chosen with the
analysis of the Primer Express version 1.5 (Applied Biosystems).
Total CTGF, endogenous CTGF, TGF-b1, COL4A1, COL4A3, fibro-
nectin, MMP-2, TIMP-1 and TIMP-2 mRNA expressions were
evaluated with the following primers and probes: total CTGF forward
primer, 50-ttcccgagaagggtcaagct-30; total CTGF reverse primer, 50-tccttg
ggctcgtcacaca-30; total CTGF probe, 50-FAM-cctgggaaatgctgcaaggagtgg-
TAMRA-30;47 endogenous CTGF forward, 50-ggtcaaatccctgttggtgaa-30;
endogenous CTGF reverse, 50-aaagaagcagcaagcacttcct-30; endogenous
CTGF probe, 50-FAM-ttaagaaatggctggctcagggtaaggtcc-TAMRA-30 (acce-
ssion number M70642); TGF-b1 forward, 50-gacgtcactggagttgtacgg-30;
TGF-b1 reverse, 50-gctgaatcgaaagccctgt-30; TGF-b1 probe, 50-FAM-agtgg
ctgaaccaaggagacggaa-TAMRA-30;46 COL4A1 forward, 50-ggcaggtcaagttct
agcgtaga-30; COL4A1 reverse, 50-gtgagtttgaggaaagctggtgtt-30; COL4A1
probe, 50-FAM-ataaagcgcacttggttttcgtctctgga-TAMRA-30;48 COL4A3
forward, 50-tgtggatgcacggtgtgtt-30; COL4A3 reverse, 50-gttctcttcacggtgtgc
ttga-30; COL4A3 probe, 50-FAM-ccttccatctcctccctgacaccttagact-TAM
RA-30 (accession number AF169387); fibronectin forward, 50-atcatttca
tgccaaccagtt-30; fibronectin reverse, 50-tcgcactggtagaagttcca-30; fibronec-
tin probe, 50-FAM-ccgacgaagagcccttacagttcca-TAMRA-30;13 MMP-2
forward, 50-cctggtttcaccctttctgct-30; MMP-2 reverse, 50-cgagcgaagggca
tacaaa-30; MMP-2 probe, 50-FAM-cccagatacctgcaccaccttaactgttgc-
TAMRA-30 (accession number AK148184); TIMP-1 forward, 50-atggaaa
gcctctgtggatatg-30; TIMP-1 reverse, 50-ggcccgtgatgagaaactc-30; TIMP-1
probe, 50-FAM-cacaagtcccagaaccgcagtga-TAMRA-30 (accession number
BC008107); TIMP-2 forward, 50-aggcgttttgcaatgcag-30; TIMP-2 reverse,
50-ccggaatccacctccttct-30; and TIMP-2 probe, 50-FAM-cgtagtgatcagagcc
aaagcagtgagc-TAMRA-30 (accession number M82858). Expression of
each mRNA was normalized for 18S ribosomal RNA (Taqman
ribosomal RNA control reagents; Applied Biosystems).
Western blot analysis
Western blot analysis was performed as described18 with some
modifications. Isolated glomerular extracts were electrophoresed
and transferred onto Immobilon filter (Millipore, Bedford, MA,
USA). Filters were incubated with human monoclonal anti-CTGF
antibody (FibroGen Inc.)20 for 1 h, and immunoblots were then
developed using horseradish peroxidase-linked donkey anti-human
immunoglobulin (Amersham, Arlington Heights, IL, USA) and a
chemiluminescence kit (Amersham). b-Actin (antibody from
Sigma-Aldrich) was used as an internal control.
Zymography
MMP activity in 30 mg of glomerular extract was measured by
gelatin zymography as previously described.49 Briefly, isolated
glomeruli were lysed on ice in zymography buffer containing
50 mM Tris-HCl, 150 mM NaCl, 10 mM CaCl2, 0.05% Brij35,
10 mg ml1 leupeptin, and 1 mM PMSF. The lysates were centrifuged
at 15 000 r.p.m., and the supernatants and gelatinase zymography
standards (Millipore, Temecula, CA, USA) were separated by
10% polyacrylamide gels containing 0.1% gelatin (Invitrogen).
After gel electrophoresis, gels were incubated overnight at 371C
in zymogram developing buffer (Invitrogen) and stained with
Coomassie stain.
Statistical analysis
Data are expressed as the mean±s.e. Statistical analysis was
performed using one-way ANOVA. A P-valueo0.05 was considered
statistically significant.
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